Does Rallies show 13F holders for BIO?

Yes. Rallies tracks hedge fund and 13F ownership data for BIO, including fund names, share counts, latest tracked quarter, and position changes when available.

Is BIO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BIO. It does not provide personalized investment advice.

BIO (Bio-Rad Laboratories, Inc.Class A) Stock Analysis - Hedge Fund Holdings

Bio-Rad Laboratories, Inc.Class A (BIO) is a publicly traded Healthcare sector company. As of May 21, 2026, BIO trades at $287.16 with a market cap of $7.54B and a P/E ratio of 10.31. BIO moved +2.27% today. Year to date, BIO is -10.70%; over the trailing twelve months it is +16.52%. Its 52-week range spans $211.43 to $387.99. Analyst consensus is buy with an average price target of $303.33. Rallies surfaces BIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns BIO stock?

Hedge funds tracked by Rallies that own BIO include Mangrove Partners, Centerbook Partners, Eisler Capital, Pinebridge Investments, and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Bio-Rad Laboratories, Inc.Class A.

BIO Key Metrics

Key financial metrics for BIO
Metric	Value
Price	$287.16
Market Cap	$7.54B
P/E Ratio	10.31
EPS	$27.87
Dividend Yield	0.00%
52-Week High	$387.99
52-Week Low	$211.43
Volume	451.75K
Avg Volume	0
Revenue (TTM)	$2.58B
Net Income	$759.90M
Gross Margin	51.87%

Top Hedge Funds Holding BIO

Mangrove Partners holds 126.85K shares of BIO, changed +0.00% as of Mar 31, 2026.
Centerbook Partners holds 7.82K shares of BIO, changed +155.85% as of Mar 31, 2026.
Eisler Capital holds 3.13K shares of BIO, changed +0.00% as of Dec 31, 2023.
Pinebridge Investments holds 2.45K shares of BIO, changed -41.79% as of Mar 31, 2025.
Panagora Asset holds 2.00K shares of BIO, changed -0.05% as of Sep 30, 2024.

Latest BIO News

Bio-Rad slides after Q1 results as 2026 revenue and margin outlook cut — May 1, 2026
Bio-Rad Cuts 2026 Revenue Forecast to -3%–0.5%, Q1 EPS Falls to $1.89 — May 1, 2026
Bio-Rad slides ahead of April 30 earnings as caution builds after Citi downgrade — Apr 28, 2026
Bio-Rad drops as Sartorius Q1 results ripple through Bio-Rad’s huge stake — Apr 23, 2026
Bio-Rad (BIO) jumps 3% without new filing, as sector bid and positioning lift shares — Apr 13, 2026

BIO Analyst Consensus

3 analysts cover BIO: 0 strong buy, 1 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $303.33.

Common questions about BIO

Who owns BIO stock?: Hedge funds tracked by Rallies that own BIO include Mangrove Partners, Centerbook Partners, Eisler Capital, Pinebridge Investments, and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Bio-Rad Laboratories, Inc.Class A.
Does Rallies show 13F holders for BIO?: Yes. Rallies tracks hedge fund and 13F ownership data for BIO, including fund names, share counts, latest tracked quarter, and position changes when available.
Is BIO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BIO. It does not provide personalized investment advice.